Skip to content
Finance Investment, Oil Mining Resources

BlinkLab Limited (ASX:BB1) Marks its ASX Debut During World Autism Month, Championing AI-Powered Mental Healthcare Innovations

BlinkLab Limited (ASX:BB1) 2 mins read

Sydney, Australia, 4 April 2024 – In alignment with World Autism Month, BlinkLab Limited (ASX:BB1) proudly announces its listing on the Australian Securities Exchange (ASX) today, 4 April 2024, at 12:00pm AEDT (9:00am AWST). Founded by visionary neuroscientists at Princeton University, BlinkLab has carved a niche in advancing mental healthcare through the development of smartphone-based AI-powered solutions for the early diagnosis of autism, ADHD, and other neurodevelopmental conditions.

 

This strategic listing coincides with a period of heightened awareness and advocacy for autism, amplifying the significance of BlinkLab’s mission. Leveraging the capital raised, the company aims to complete a crucial FDA Class II medical device registration study in autism, in collaboration with top US university hospitals.

 

BlinkLab’s Chairman, Brian Leedman, expressed his excitement about the company’s innovative impact, saying, "I believe BlinkLab is the next groundbreaking venture in digital healthcare. Our innovative approach leverages the power of smartphones, AI and machine learning to deliver autism screening tests specifically designed for children as young as 18 months old. This will aid healthcare providers to identify these children at a much younger age than presently available providing a pathway to effective treatment and better outcomes for the child and their families. This cutting-edge digital technology is poised to capture the imagination of major industry players, eager to embrace transformative solutions in healthcare."

 

BlinkLab’s proprietary testing platform utilises smartphones to deliver and analyze stimuli with unprecedented precision. This approach has yielded promising results in clinical trials, demonstrating a high degree of accuracy in diagnosing autism.

 

Henk-Jan Boele, BlinkLab’s Cofounder and CEO, remarked on the timing of the ASX listing, "Our ASX debut during World Autism Month is a poignant reminder of our dedication to bridging the gap between groundbreaking science and the real-world needs of families navigating neurodevelopmental challenges."

 

With plans to embark on a registrational study for FDA 510(k) registration and explore diagnostic solutions for additional conditions, BlinkLab envisions a future where AI-driven tools are integral to personalised, accurate mental healthcare.


About us:

BlinkLab Limited (ASX:BB1), a pioneer in the realm of AI-powered mental healthcare diagnostics, was founded on the innovative work of neuroscientists from Princeton University. Specializing in smartphone-based diagnostics, BlinkLab is committed to improving the early detection and treatment of neurodevelopmental disorders. Positioned at the intersection of technology and healthcare, BlinkLab strives to make a meaningful difference in the lives of individuals and families affected by these conditions.


Contact details:

Jane Morgan

jm@janemorganmanagement.com.au

Media

More from this category

  • Community, Finance Investment
  • 17/04/2024
  • 11:28
Communico Media Group P/L

Place Branding Australia 2024 to Illuminate Vivid Sydney

FOR IMMEDIATE RELEASE Sydney, Australia – April 18, 2024 – Place Branding Australia 2024, the premier conference on placemaking and community identity, will be a highlight of this year's Vivid Sydney festival. The conference will delve into how communities across Australia and beyond use their unique identities to drive economic and social growth, attract residents, and overcome challenges. "Vivid Sydney is the ideal backdrop for exploring the power of place branding," says conference curator Stu Speirs. "The festival's success is a testament to its deep connection with Sydney's identity as a place. This conference offers a front-row seat to a…

  • Finance Investment, Medical Health Aged Care
  • 17/04/2024
  • 11:12
Little Green Pharma

Medicinal cannabis company Little Green Pharma (ASX:LGP) records record quarterly revenue and cash receipts

RECORD REVENUE AND CASH RECEIPTS FOR QUARTER AND FINANCIAL YEAR, POSITIVE OPERATING CASHFLOW FOR FY24 OF $0.5 MILLION Highlights Record quarterly cash receipts of…

  • Contains:
  • Finance Investment, Oil Mining Resources
  • 17/04/2024
  • 10:12
Pantera Minerals Limited (ASX: PFE)

Pantera Minerals (ASX: PFE) – 1,500 New Acres added within the Primary Lithium Target Area

April 17, 2024 – ASX listed minerals explorer, Pantera Minerals Limited (ASX: PFE) is pleased to announce the successful leasing of an additional 1,500…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.